子宫内膜癌雌、孕激素受体和C-erbB-2检测的临床意义

目的 检测子宫内膜癌组织中雌激素受体(ER)、孕激素受体(PR)及癌基因蛋白C-erbB-2表达的阳性率并探讨其与预后的关系.方法 用免疫组织化学法对32份子宫内膜癌标本进行了ER、PR及C-erbB-2的检测.结果 子宫内膜癌组织中ER、PR、C-erbB-2的阳性率分别为53.1%、50.0%、46.9%.ER、PR的阳性表达率与癌组织的细胞分化程度有关,随着子宫内膜癌组织学分级的增高,ER、PR阳性表达率逐渐降低,C-erbB-2的阳性表达率与肿瘤病理分级呈正相关,与ER、PR表达呈负相关.结论 ER、PR、C-erbB-2均反映了子宫内膜癌的生物学行为,其测定对预测预后、指导选择内分泌治疗具有重要意义.     

Effect of progestin therapy on the level of cytoplasmic receptors in patients with cancer of the corpus uteri

Correlations were identified between tumor morphobiochemical characteristics and basic parameters of reproductive homeostasis in 256 cases of endometrial carcinoma. A correlation was established between the levels of cytoplasmic receptors to estradiol (ER) and progesterone (PR), on the one hand, and morphological differentiation and spontaneous secretion in tumor tissue, on the other. A direct correlation was found between ER and metastatic spread to regional lymph nodes, and no correlation--between ER and PR and major parameters of reproductive homeostasis. A significant decrease in ER, PR, gonadotropins, estradiol and colpocytological reaction indexes followed hormone therapy with hydroxyprogesterone capronate and medroxyprogesterone acetate. The criteria of endometrial carcinoma patients sensitivity to progestin therapy were as follows: ER and PR levels--more than 30.0 fmol/mg protein, estradiol--more than 30-50 pg/ml and colpocytological index--over 40%.     

Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma

BACKGROUND: The aim of this study was to compare the concordance between immunohistochemical (IHC) and biochemical (RIA) methods for determining hormone receptor status in patients with endometrial carcinoma and to determine whether IHC expression of estrogen and progesterone receptors (ER and PR) has prognostic significance. METHODS: Paraffin blocks were obtained from patients diagnosed with endometrial carcinoma between 1987 and 1991. IHC analysis for ER and PR expression was performed and scored based on staining intensity and the percentage of tumor cells with nuclear staining. Biochemical assays were performed on frozen tissues. Concordance between the two methods was evaluated and hormone receptor status was correlated with tumor grade, stage, recurrence and survival. RESULTS: ER and PR expression, determined by IHC, correlated well with RIA levels (Spearmans correlation coefficient, P = 0.006 and 0.0005, respectively). Determination of ER and PR expression by both methods was correlated with tumor grade. Hazards ratios revealed that the absence of ER and PR expression, determined by both IHC and RIA, independently correlated with recurrence in early stage disease (P < 0.05). CONCLUSIONS: Historically, receptors have been determined by RIA. In this study, IHC and RIA were equally suitable for determination of ER and PR. This is significant clinically as IHC has several advantages over RIA, including easier processing, lower cost, greater speed, and applicability to fixed tissue samples. In addition, ER negative status was predictive of the recurrence of Stage I tumors independent of tumor grade. ER status may aid the clinician in planning treatment when adjuvant treatment is controversial.     

雌、孕激素受体在子宫内膜良恶性肿瘤组织中的表达及其意义

目的 检测分析雌激素受体(ER)、孕激素受体(PR)在子宫内膜良恶性肿瘤组织中的表达情况,探讨ER、PR与子宫内膜癌发生、发展的关系.方法 采用免疫组织化学SP法对58例子宫内膜癌、37例子宫内膜非典型增生,25例子宫内膜单纯性增生,25例正常子宫内膜标本进行ER和PR的检测.结果 ER、PR的阳性表达率在正常子宫内膜分别为24.0%、20.0%;单纯性增生52.0%、44.0%;非典型增生70.3%、64.9%;子宫内膜癌62.1%、56.8%.正常内膜到单纯型增生及非典型增生阳性表达率呈阶梯样上升,子宫内膜癌略低于非典型增生,两者均明显高于正常内膜(P＜0.05).子宫内膜癌ER、PR强阳性表达率在不同组织分级中高分化Ⅰ级53.8%、53.8%;中分化Ⅱ级27.8%、22.2%,低分化Ⅲ级7.1%、0,低分化低表达.高分化高表达,Ⅰ级与Ⅲ级差异有统计学意义(P＜0.05).ER、PR强阳性表达率在年龄≤50岁患者41.9%、38.7%,＞50岁25.9%、22.2%,≤50岁组高于＞50岁组,但差异无统计学意义.临床各分期之间差异无统计学意义(P＞0.10).结论 正常子宫内膜到非典型增生、癌变过程中出现ER、PR异常高表达.ER、PR表达高低与癌组织分化程度密切相关,可能与子宫内膜癌的发生、预后有一定关系.     

子宫内膜癌bcl—2基因表达及其与PR、ER关系的研究

[目的]探讨bcl-2与子宫内膜癌发生、发展的关系以及与PR、ER在致癌过程中有无内在联系。[方法]采用免疫组化SP法检测了58例子宫内膜癌组织中bcl-2及PR、ER的表达。[结果]子宫内膜癌中bcl-2的阳性表达率为56.9%,PR、ER的阳性表达率分别为55.2%、46.6%。bcl-2的阳性表达与组织学分级有关,而与其他临床病理学特征无关;PR的阳性表达与子宫内膜癌的临床病理特征都有关;ER的阳性表达只与肌层浸润深度有关,bcl-2的阳性表达与PR呈现正相关。[结论]bcl-2可能与子宫内膜癌的发生和分化特性有关;PR可能在子宫内膜癌的发生、发展中起作用。     

孕激素受体与子宫内膜癌临床病理学特征及预后关系的研究

目的：研究子宫内膜癌组织中类固醇激素受体的表达及其与临床病理学特征及预后的关系。方法：采用免疫组化S－P法测定62例子宫内膜癌组织中雌激素受体（ER）和孕激素受体（PR）的表达,并评价其与患者年龄、临床手术分期、组织学分级和生存率的关系。结果：62例中,34例（54．84％）PR阳性,30例（48．39％）ER性。PR的阳性表达与临床手术分期（P＜0．01）,组织学分级（P＜0．05）、肌层浸润深度（P＜0．01）及生存率（P＜0．05）相关;ER的阳性表达只与肌层的浸润深度明显相关（P＜0．05）。结论：PR的阳性表达可能是独立于其他临床学参数的重要预后指标。     

Measurement of estrogen receptor and progesterone receptor in human endometrium and endometrial carcinoma

The concentration of cytosol estrogen receptors (ER) and progesterone receptors (PR) in the endometrium of the normal menstrual cycle and endometrial carcinoma, were measured by Enzyme Immunoassay (EIA) using monoclonal antibody, and were compared with Dextran Coated Charcoal (DCC) method. In DCC method, maximum binding sites were estimated according to Scatchard plot analysis. Following results were obtained in this study. 1) In the normal endometrium obtained from 20 cases, the correlation coefficients for ER and PR were 0.907 and 0.778, respectively. Regression lines were as follows; ER (EIA) = 1.68 (DCC) + 19.1 fmol/mg protein and PR (EIA) = 0.13 (DCC) + 24.8 fmol/mg protein. A good correlation was found between the two methods in ER assay. 2) In the normal menstrual cycle, DCC values and EIA values of ER were increased in proliferative phase, and were decreased in secretory phase. DCC values of PR were increased in proliferative phase and not decreased in secretory phase, but EIA values of PR were not remarkably changed. 3) In the endometrial carcinoma obtained from 14 cases, there was good correlation between EIA and DCC values in ER assay (r = 0.941), but correlation between the two methods was not found in PR assay. 4) In relation of histology, positive rates were highest in patients with well differentiated types, and in relation of clinical stage, positive rates were higher in the patients with early stages than progressive stages. These results suggest that EIA is as useful as DCC in ER assay in normal endometrium and endometrial carcinoma.     

Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression

BACKGROUND: To examine the steroid hormone dependent growth mechanism of human endometrial hyperplasia and carcinoma, expression levels of steroid receptor cofactors, such as coactivators (steroid receptor coactivator 1 [SRC-1] and p300/cyclic AMP-response element-binding protein (p300/CBP]) and corepressors (nuclear receptor corepressor [NCoR] and silencing mediator for retinoid and thyroid-hormone receptors [SMRT]), were investigated. METHODS: The expression levels of cofactors were examined immunohistochemically using 20 samples of normal endometria, 36 samples of hyperplastic endometria, and 58 of malignant endometria and were compared with the expression levels of estrogen receptor (ER), progesterone receptor (PR), and a proliferation marker, Ki-67. RESULTS: In samples of normal endometria, the expression of coactivators was observed diffusely in glandular cells in the proliferative phase, with a mean positivity index (PI) of 81.8 for SRC-1 and 91.3 for p300/CBP, whereas expression levels decreased in endometrial hyperplasia (PI: SRC-1, 58.9; p300/CBP, 83.8) and endometrial carcinoma (PI: SRC-1, 45.0; p300/CBP, 55.4). In endometrial hyperplasia, there was a significant correlation between the expression of ER and SRC-1 or p300/CBP. In contrast, there were no significant statistical or topologic correlations between the expression of coactivators and the expression of ER/PR in endometrial carcinoma. The expression of corepressors generally was limited, except for elevated expression of NCoR in endometrial hyperplasia (PI, 23.8). CONCLUSIONS: The current study showed that expression levels of the steroid receptor coactivators SRC-1 and p300/CBP were reduced in endometrial carcinoma compared with normal and hyperplastic endometrium. In addition, topologic coexpression of both coactivators and ER/PR was lost in endometrial carcinoma. Accordingly, limited response to sex steroids in patients with endometrial carcinoma may be ascribed to the dissociation of cofactors and ER/PR.     

Correlation between receptor status and results of treatment in endometrial carcinoma

In the course of immunohistochemical assay of estrogen (ER), progesterone (PR) and oncoprotein HER-2/neu receptors, PR+ expression was identified in 52% of 50 patients with endometrial carcinoma. A direct correlation between ER and PR levels (i = 0.7) was established (ER+/PR(+)--26.0%; ER-/PR(-)--42.0%; ER-/PR(+)--26.0%; ER+/PR(-)--6.0%). In the ER+/PR+ and--ER-/PR+ groups, adjuvant therapy with progestins was carried out (3-year-survival--95.3% (p < 0.05)); recurrence rate--8.0%. Inverse correlations were characteristic of ER and HER-2/neu (i = -0.4) and PR and HER-2/neu (i = -0.114). Adjuvant polychemotherapy was administered in 12.2% of cases of HER-2/neu over-expression. That group revealed a drop in 3-year survival from 85.5 to 41.7% and relapse in half of the patients.     

Apoptosis,proliferation, and hormone receptors in endometrial carcinoma: results depending on methods of analysis

Apoptosis and proliferation were studied in 29 endometrial adenocarcinomas of the endometrioid type and characterized by the immunohisto-chemical pattern of estrogen receptor (ER) alpha and progesterone receptor (PR) expression. Intratumoral heterogeneous distribution of both ER and PR as well as of the proliferation marker Ki-67 was studied and quantified. Both density and heterogeneity of the two steroid receptors and Ki-67 varied, depending on the histological malignancy grade (grades 1-3, or G1-3); interestingly, however, the apoptotic index (Ai) was in the same range for all grades. Receptor staining was evaluated by three different methods: i) counting the percentage of stained cells (staining index), according to stereological principles; ii) the mixed method, a combination of the staining index results and ranking staining intensity; and iii) a superficial and rapid visual scoring. The three methods gave equal results. Apoptotic cells and bodies were generally scattered in the endometrial carcinoma but more frequently observed adjacent to necrotic foci. Bcl-2, known as anti-apoptotic factor, showed no correlation to apoptotic index, Ki-67 expression, ER, or PR. Overexpression of p53 was seen in two tumors of grade 3. In a detailed study of intra-tumoral microfoci performed on consecutively taken tissue sections, a higher staining index of both ER and PR was found in the areas of maximal proliferation compared with the areas of minimal proliferation in tumors of grades 1-2, but not in G3 tumors. Other covariations were also found when non-specified areas were studied. The Ki-67 index was both higher and more heterogeneous in G2-3 tumors than in G1 tumors. Our results indicate that there is an increasing discrepancy between cell death and cell proliferation with progressing tumor grade, which may contribute to the differences in tumor aggressivity.     

p27~(kipl)蛋白与雌、孕激素受体在子宫内膜组织中的表达及其意义

目的　探讨 p2 7kipl、雌激素受体 (ER)与孕激素受体 (PR)在子宫内膜癌中的表达及意义。方法　用免疫组化法检测 6 6例子宫内膜癌、2 9例子宫内膜非典型增生病变和 31例正常子宫内膜组织中p2 7kipl蛋白及其癌组织中ER和PR的表达。结果　在癌组织中p2 7kipl的表达率为 5 3.0 % ,明显低于非典型增生病变的 75 .8%和正常子宫内膜的 87.1% ,并与其分级有关 ;ER和PR的表达与p2 7kipl相似。结论　p2 7kipl与此癌的发展和恶性程度有关 ,这对其治疗和预后有参考价值。     

Expression of ER,PR, and Her-2/neu in Endometrial Cancer: A Clinicopathological Study

Objective: To determine any association between expression of estrogen receptor (ER), progesterone receptor(PR), and Her-2/neu and clinicopathological features, including survival, of endometrial carcinoma (EMC)patients. Methods: Samples of formalin-fixed, paraffin-embedded tissue of 108 patients with EMC treated atour institution between January 1994 and December 2007 were immunohistochemically studied. Results: ER,PR, and Her-2/neu expression were positive in 59.3%, 65.7% and 2.8% of cases, respectively. Positive ERexpression was significantly associated with grade I-II tumor while PR expression was linked with endometrioidhistology, grade I-II tumor, less myometrial invasion (MI) and negative lymph node involvement. Her-2/neuexpression was significantly associated with deep MI, while positive ER and negative Her-2/neu expression incombination was significantly associated with longer disease-free and overall survival. Conclusion: ER expressionis a good prognostic factor while Her-2/neu expression appears to be a poor indicator for both disease-free andoverall survival, while PR tended to show favorable influence for only disease-free survival of Thai EMCs.     

Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium

To evaluate the role of c-jun and c-myc proto-oncogenes in normal, hyperplastic and neoplastic endometrium in relation to estrogen receptor (ER) status and to investigate whether these genes can be related to other histopathological features of endometrial carcinoma, 32 endometrial carcinomas, 38 endometrial hyperplasias and 22 cyclic endometria (10 proliferative and 12 secretory) were evaluated histologically. Endometrial hyperplasia cases were classified as simple and complex hyperplasia without atypia, and atypical hyperplasia. Endometrial carcinoma cases were subtyped according to the International Society of Gynecological Pathologists. Modified FIGO system was used for both grading and staging. Immunohistochemical examination was performed using antibodies to ER-alpha, c-myc and c-jun with streptavidin-biotin-peroxidase technique. The mean percentage of ER-alpha positive cells changed cyclically during the menstrual cycle, and it was the highest (96%) and the lowest (31.6%) in proliferative and carcinomatous endometrium, respectively. There was a statistically significant difference between proliferative and secretory phases and proliferative and carcinomatous endometrium in relation to ER-alpha staining (p<0.05). There was also a statistically significant difference with respect to ERalpha reactivity between secretory phase and each hyperplastic group, as well as between the carcinoma group and each hyperplastic group (p<0.05). Although not significant, the mean percentage of c-myc expressing cells in the carcinoma group was higher (15.3%) than that of proliferative phase and hyperplastic groups. The mean percentage of c-jun positive cells in proliferative endometrium was slightly higher than in secretory endometrium, and it was the highest in atypical hyperplastic endometrium (28.3%), but there was no statistically significant difference between the groups. In carcinoma cases, a positive correlation was observed between c-jun positivity and tumor grade (p=0.027, r=0.3908), but such a correlation with c-myc was not found. A positive correlation was detected between ER-alpha and c-myc expression (p=0.038, r=0.3686). A progressive loss of ER seems to be correlated with increasing malignant transformation. C-myc expression might play a role in the development of endometrial carcinoma via ER. The association between c-jun and ER appears to be lost in endometrial carcinoma. The relationship between c-myc, c-jun and ER appears to be altered in endometrial carcinoma compared to that of menstrual endometrium.     

STAT3与雌、孕激素受体在子宫内膜癌中表达的相关性

目的探讨孕激素受体（PR）、雌激素受体（ER）与信号转导及转录活化因子3（STAT3）在子宫内膜癌患者中的表达情况及其相关性。方法选取30例经病理组织学证实为子宫内膜癌的患者为研究对象,并选取30例健康体检妇女为对照组,采用免疫组化法测定2组子宫内膜标本中ER、PR、STAT3表达情况,并分析三者相关性。结果子宫内膜癌组织中ER、PR、STAT3阳性表达率显著高于对照组,差异有统计学意义（P〈0．05）。子宫内膜癌中STAT3、ER表达均与肿瘤临床分期、病理分级、淋巴结转移有关（均P〈0．05）;而PR则与临床分期及病理分级有关（均P〈0．05）。经相关性分析可知,STAT3与ER激素呈正相关（γ=0．452,P=0．000）,与PR激素无关（γ=0．1378,P=0．071）。结论子宫内膜癌的发生与ER、PR、STAT3过度表达有关,而STAT3的表达与雌激素调控有密切关系。     

VEGF、bFGF和ER在子宫内膜癌的表达

目的探讨血管内皮细胞生长因子(VEGF)的表达与子宫内膜癌临床病理参数和预后的关系,以及其与雌激素受体（ER）和碱性成纤维细胞生长因子(bFGF)表达之间的关系。方法采用免疫组化SP法检测66例子宫内膜癌和19例正常子宫内膜的石蜡切片VEGF、ER和bFGF的表达。结果子宫内膜癌VEGF的阳性表达率为80.3%,其表达与组织学分级呈正相关(r=0.4021,P＜0.01);ER表达与组织学分级呈负相关(r=-0.2455,P＜0.05);VEGF与bFGF的表达呈正相关（r=0.2939,P＜0.05）。ER阴性表达比ER阳性表达的患者预后差（P＜0.05）。ER表达与VEGF和bFGF的表达无显著相关性。结论VEGF是子宫内膜癌重要的血管生成因子,ER表达与子宫内膜癌的预后有关,但与bFGF和VEGF的表达无关。     

Expression of ER,PR, C-erbB-2 and Ki-67 in Endometrial Carcinoma and their Relationships with the Clinicopathological Features

Background: To analyze the expression of estrogen receptors (ER), progesterone receptors (PR), C-erbB-2and Ki-67 in endometrial carcinoma (EC) and their relationships with the clinicopathological features. Materialsand Methods: Sixty-seven EC samples, 53 normal endometrial samples and 53 atypical hyperplasia endometrialsamples were all selected in Shaanxi Provincial People’s Hospital from Jun., 2012 to Jun., 2014. The expression ofER, PR, C-erbB-2 and Ki-67 in EC tissue, normal endometrial tissue and atypical hyperplasia endometrial tissuewas respectively detected using immunohistochemical SP method. The relationships between the expression of ER,PR, C-erbB-2 and Ki-67 and the patients’ clinicopathological features as well as their correlations in EC tissuewere also analyzed. Results: The positive expression rates of ER and PR in EC tissue were 44.8% and 41.8%,respectively, dramatically lower than in atypical hyperplasia endometrial tissue and normal endometrial tissue(P<0.01). The positive expression rates of C-erbB-2 and Ki-67 in EC tissue were 80.6% and 64.2%, respectively,significantly higher than in atypical hyperplasia endometrial tissue and normal endometrial tissue (P<0.01).In EC tissue, the expression of ER and PR was closely associated with the differentiated degrees and depth ofmyometrial invasion (P<0.05), while that of C-erbB-2 and Ki-67 with the clinical staging, differentiated degrees,depth of myometrial invasion and presence or absence of lymph node metastasis (P<0.05). Spearman correlationanalysis further displayed that the expression of ER was positively correlated with PR (r=0.393, P=0.001), butnegatively with C-erbB-2 and Ki-67 (r=-0.469, P=0.000; r=-0.329, P=0.007); The expression of PR was negativelycorrelated with C-erbB-2 and Ki-67 (r=-0.273, P=0.025; r=-0.251, P=0.041), but that of C-erbB-2 positivelywith Ki-67 (r=0.342, P=0.005). Conclusions: Abnormal expression of ER, PR, C-erbB2 and Ki-67 might playan important role in endometrial malignant transformation and cell differentiation, so their joint detection islikely to be a comprehensive combination of immune factors, which is of great importance for EC prognosis.     

影响子宫内膜腺癌预后相关因素分析

目的应用多指标、综合分析方法评价影响子宫内膜癌预后因素的临床意义。方法采用肿瘤实验室检测和临床治疗学随访相结合方法观测临床分期等７项指标与预后的关系。结果临床分期、病理分级、肌层浸润、雌激素受体（ＥＲ）、孕激素受体（ＰＲ）和ＤＮＡ倍体与子宫内膜癌预后和五年生存率间高度相关，而血管内癌栓与预后无相关性。结论正确的临床分期、病理分级和肌层浸润是影响内膜癌预后的重要指标，ＥＲ、ＰＲ、ＤＮＡ与治疗后预后有相关性。     

Immunohistochemical study of the human 17 beta-hydroxysteroid dehydrogenase and steroid receptors in endometrial adenocarcinoma.

17 beta-Hydroxysteroid dehydrogenase (17HSD) and estrogen (ER) and progestin (PR) receptors were analyzed immunohistochemically in tissue specimens of 66 patients with endometrial adenocarcinoma. Plasma steroid concentrations were correlated to immunohistochemical data. 17HSD was detected in 48% of the specimens and was stained in the cytoplasm of epithelial cells. The tissues were characterized by a heterogeneous staining pattern for 17HSD. In some patients, intensively stained epithelial cell clusters were seen, indicating that local factors were responsible for the expression of the protein. Poorly differentiated adenocarcinoma specimens tended to have no 17HSD more frequently than did well or moderately differentiated tissues. ER and PR were detectable in 24% and 28% of patients, respectively, and were localized in the nuclei of epithelial and stromal cells. There was a significant correlation between 17HSD and PR staining and an inverse correlation between plasma progesterone concentrations and 17HSD staining. This is contrary to the data obtained with normal endometrium. The main reason for this inverse relation between endometrial 17HSD staining and plasma progesterone concentrations was that, in some postmenopausal patients with low plasma progesterone concentrations, intense staining for 17HSD was detectable in the endometrial carcinoma specimens. This indicates a major difference in the regulation of 17HSD expression in endometrial adenocarcinomas, compared with normal tissues of premenopausal women.     

The occurrence of multiple steroid hormone receptors in disease-free and neoplastic human ovary

The cytoplasmic receptors for 17 beta-estradiol (ER), 5 alpha-dihydrotestosterone (AR), progesterone (PR), and cortisol (GR) have been quantified in 36 specimens from the human ovary (13 disease-free, 5 benign, and 18 malignant) by a dextran-coated charcoal (DCC) technique. The occurrence of receptor-positive biopsies were: ER 46%, AR 85%, PR 54%, GR 92%, in normal tissue; ER 40%, AR 100%, PR 20%, GR 50%, in benign tumors; and ER 67%, AR 72%, PR 50%, GR 88%, in malignant lesions. Furthermore, the simultaneous occurrence of ER and PR in malignant tumors was 50% yet all four receptors were found to be present only in 44% of the cases. The findings reported here on the strong correlation existing between ER and PR presence or amount agree with previous observations on normal and neoplastic specimens from human breast and endometrial tissues.     

Evaluation of Expression of the PTEN Gene, Oestrogen and Progesterone Receptors as Diagnostic and Predictive Factors in Endometrial Cancer

Endometrial cancer belongs to the commonest malignancy in females after breast cancer, malignant neoplasm of female genitals in Europe and North America but there is still not significant improvement as far as the curability of this neoplasm is concerned, especially its advanced forms. That is why there is need to define new factors that could be not only diagnostic but also predictve factors. In present study we analyzed the mRNA PTEN expression by quantitative real-time polymerase chain reaction (Q-PCR) in 123 women of endometrial carcinoma and 14 women of control group. Moreover we assessed oestrogen (ER) and progesterone receptors (PgR) in all cases. We defined the correlation between expression of PTEN gene and receptors and between PTEN expression and maturity grade of cancer. Neoplasm advancement grade G1 was diagnosed in 82.11 % of patients (n?=?101), G2 in 9.76 % of patients (n?=?12) and G3 in 8.13 % of patients (n?=?10). Presence of ER and PgR and decreased expression of PTEN gene was found in majority of patients with endometrial cancer (79.12 % and 59.34 % respectively) and the most numerous group was with weak expression of ER and strong expression of PgR. There was no statistically significant difference in gene expression depending on receptors expression nor maturity grade of cancer (p?>?0.05). Evaluation of expression of PTEN gene may turn out to be a very useful tool aimed at qualifying patients for different therapies of endometrial cancer and at searching of new diagnostic and therapeutic methods of this cancer independently on its receptor status nor maturity grade of cancer.